Concepedia

Jason D. Brubaker

JD

15

Publications

1.3K

Citations

13

H-Index

2003

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Blueprint Medicines (United States)

Harvard University

University of Connecticut

Jason D. Brubaker is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, drug discovery, and organic chemistry.

Top concepts

Publications per year

2003–2024

15

Publications

15

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers

Vivek Subbiah, Justin F. Gainor, Rami Rahal et al. · Cancer Discovery · 2018 · 386 citations

A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics

Mark G. Charest, C. Lerner, Jason D. Brubaker et al. · Science · 2005 · 294 citations

, , +11

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 146 citations · Full text

A Robust Platform for the Synthesis of New Tetracycline Antibiotics

Cuixiang Sun, Qiu Wang, Jason D. Brubaker et al. · Journal of the American Chemical Society · 2008 · 128 citations · Full text

A Practical, Enantioselective Synthetic Route to a Key Precursor to the Tetracycline Antibiotics

Jason D. Brubaker, Andrew G. Myers · Organic Letters · 2007 · 77 citations · Full text

Rows per page

1–5 of 15